171 related articles for article (PubMed ID: 28163023)
1. A novel urotensin II receptor antagonist, KR-36996, improved cardiac function and attenuated cardiac hypertrophy in experimental heart failure.
Oh KS; Lee JH; Yi KY; Lim CJ; Park BK; Seo HW; Lee BH
Eur J Pharmacol; 2017 Mar; 799():94-102. PubMed ID: 28163023
[TBL] [Abstract][Full Text] [Related]
2. The orally active urotensin receptor antagonist, KR36676, attenuates cellular and cardiac hypertrophy.
Oh KS; Lee JH; Yi KY; Lim CJ; Lee S; Park CH; Seo HW; Lee BH
Br J Pharmacol; 2015 May; 172(10):2618-33. PubMed ID: 25597918
[TBL] [Abstract][Full Text] [Related]
3. Effects of KR-31378, a novel ATP-sensitive potassium channel activator, on hypertrophy of H9c2 cells and on cardiac dysfunction in rats with congestive heart failure.
Hwang GS; Oh KS; Koo HN; Seo HW; You KH; Lee BH
Eur J Pharmacol; 2006 Jul; 540(1-3):131-8. PubMed ID: 16729997
[TBL] [Abstract][Full Text] [Related]
4. Chronic urotensin II receptor antagonist treatment does not alter hypertrophy or fibrosis in a rat model of pressure-overload hypertrophy.
Kompa AR; Wang BH; Phrommintikul A; Ho PY; Kelly DJ; Behm DJ; Douglas SA; Krum H
Peptides; 2010 Aug; 31(8):1523-30. PubMed ID: 20452383
[TBL] [Abstract][Full Text] [Related]
5. Benzo[b]thiophene-2-carboxamide derivatives as potent urotensin-II receptor antagonists.
Lim CJ; Woo SE; Ko SI; Lee BH; Oh KS; Yi KY
Bioorg Med Chem Lett; 2016 Oct; 26(19):4684-4686. PubMed ID: 27597245
[TBL] [Abstract][Full Text] [Related]
6. Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators.
Johns DG; Ao Z; Naselsky D; Herold CL; Maniscalco K; Sarov-Blat L; Steplewski K; Aiyar N; Douglas SA
Naunyn Schmiedebergs Arch Pharmacol; 2004 Oct; 370(4):238-50. PubMed ID: 15549273
[TBL] [Abstract][Full Text] [Related]
7. Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy.
Tzanidis A; Hannan RD; Thomas WG; Onan D; Autelitano DJ; See F; Kelly DJ; Gilbert RE; Krum H
Circ Res; 2003 Aug; 93(3):246-53. PubMed ID: 12842917
[TBL] [Abstract][Full Text] [Related]
8. Effects of novel vasopressin receptor antagonists on renal function and cardiac hypertrophy in rats with experimental congestive heart failure.
Bishara B; Shiekh H; Karram T; Rubinstein I; Azzam ZS; Abu-Saleh N; Nitecki S; Winaver J; Hoffman A; Abassi ZA
J Pharmacol Exp Ther; 2008 Aug; 326(2):414-22. PubMed ID: 18467593
[TBL] [Abstract][Full Text] [Related]
9. Induction of heart failure by minimally invasive aortic constriction in mice: reduced peroxisome proliferator-activated receptor γ coactivator levels and mitochondrial dysfunction.
Faerber G; Barreto-Perreia F; Schoepe M; Gilsbach R; Schrepper A; Schwarzer M; Mohr FW; Hein L; Doenst T
J Thorac Cardiovasc Surg; 2011 Feb; 141(2):492-500, 500.e1. PubMed ID: 20447656
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Na(+)-H(+) exchange prevents hypertrophy, fibrosis, and heart failure in beta(1)-adrenergic receptor transgenic mice.
Engelhardt S; Hein L; Keller U; Klämbt K; Lohse MJ
Circ Res; 2002 Apr; 90(7):814-9. PubMed ID: 11964375
[TBL] [Abstract][Full Text] [Related]
11. Recuperative potential of cardiac muscle following relief of pressure overload hypertrophy and right ventricular failure in the cat.
Coulson RL; Yazdanfar S; Rubio E; Bove AA; Lemole GM; Spann JF
Circ Res; 1977 Jan; 40(1):41-9. PubMed ID: 137086
[TBL] [Abstract][Full Text] [Related]
12. Celiprolol, a vasodilatory beta-blocker, inhibits pressure overload-induced cardiac hypertrophy and prevents the transition to heart failure via nitric oxide-dependent mechanisms in mice.
Liao Y; Asakura M; Takashima S; Ogai A; Asano Y; Shintani Y; Minamino T; Asanuma H; Sanada S; Kim J; Kitamura S; Tomoike H; Hori M; Kitakaze M
Circulation; 2004 Aug; 110(6):692-9. PubMed ID: 15262839
[TBL] [Abstract][Full Text] [Related]
13. KR-39038, a Novel GRK5 Inhibitor, Attenuates Cardiac Hypertrophy and Improves Cardiac Function in Heart Failure.
Lee JH; Seo HW; Ryu JY; Lim CJ; Yi KY; Oh KS; Lee BH
Biomol Ther (Seoul); 2020 Sep; 28(5):482-489. PubMed ID: 32856617
[TBL] [Abstract][Full Text] [Related]
14. Effects of the new angiotensin receptor antagonist dipotassium (Z)-2-[[5-ethyl-3-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl] methyl-1,3,4-thiadiazoline-2-ylidene]aminocarbonyl]-1-cy clopentencarbox ylate on experimental cardiac hypertrophy and acute left ventricular failure.
Murakami M; Inada Y; Tazawa S; Nakao K; Komatsu H
Arzneimittelforschung; 1997 Oct; 47(10):1099-103. PubMed ID: 9368701
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological profile of KR-33028, a highly selective inhibitor of Na+/H+ exchanger.
Jung YS; Kim MY; Kim MJ; Oh KS; Yi KY; Lee S; Yoo SE; Lee BH
Eur J Pharmacol; 2006 Mar; 535(1-3):220-7. PubMed ID: 16516883
[TBL] [Abstract][Full Text] [Related]
16. Congestive heart failure and expression of myocardial urotensin II.
Douglas SA; Tayara L; Ohlstein EH; Halawa N; Giaid A
Lancet; 2002 Jun; 359(9322):1990-7. PubMed ID: 12076554
[TBL] [Abstract][Full Text] [Related]
17. Adiponectin deficiency exacerbates cardiac dysfunction following pressure overload through disruption of an AMPK-dependent angiogenic response.
Shimano M; Ouchi N; Shibata R; Ohashi K; Pimentel DR; Murohara T; Walsh K
J Mol Cell Cardiol; 2010 Aug; 49(2):210-20. PubMed ID: 20206634
[TBL] [Abstract][Full Text] [Related]
18. Effects of ACE inhibition and angiotensin II type 1 receptor blockade on cardiac function and G proteins in rats with chronic heart failure.
Yoshida H; Takahashi M; Tanonaka K; Maki T; Nasa Y; Takeo S
Br J Pharmacol; 2001 Sep; 134(1):150-60. PubMed ID: 11522607
[TBL] [Abstract][Full Text] [Related]
19. Urotensin II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases.
Onan D; Pipolo L; Yang E; Hannan RD; Thomas WG
Mol Endocrinol; 2004 Sep; 18(9):2344-54. PubMed ID: 15205471
[TBL] [Abstract][Full Text] [Related]
20. PRX-08066, a novel 5-hydroxytryptamine receptor 2B antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats.
Porvasnik SL; Germain S; Embury J; Gannon KS; Jacques V; Murray J; Byrne BJ; Shacham S; Al-Mousily F
J Pharmacol Exp Ther; 2010 Aug; 334(2):364-72. PubMed ID: 20430844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
